# Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

> **NCT04622865** · PHASE2 · UNKNOWN · sponsor: **AB Science** · enrollment: 200 (estimated)

## Conditions studied

- SARS-CoV 2
- COVID-19
- Coronavirus Disease 2019

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Isoquercetin
- **DRUG:** Best Supportive Care

## Key facts

- **NCT ID:** NCT04622865
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622865, "Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04622865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*